 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acorda Therapeutics, Inc. (NASDAQ:ACOR  Get Free Report)s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving...

Acorda Therapeutics (NASDAQ:ACOR) Shares Cross Above 200-Day Moving Average of $13.62

Acorda Therapeutics, Inc. (NASDAQ:ACOR Get Free Report) was the target of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 12,900 shares, a drop of 21.3% from the July 31st total of 16,400 shares. Based on an average trading volume of...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Sees Significant Decrease in Short Interest

Unveiling the Intrinsic Value of Acorda TherapeuticsRelated Stocks: ACOR...

Acorda Therapeutics (ACOR): A Comprehensive Analysis of Its Market Value

Analysts at StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR  Get Free Report) in a research note issued on Thursday. The brokerage set a buy rating on the biopharmaceutical companys stock. Acorda Therapeutics Stock Performance Shares of ...

Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR Get Free Report) in a research note issued on Thursday. The brokerage set a buy rating on the biopharmaceutical companys stock. Acorda Therapeutics Stock Performance Shares of NASDAQ:ACOR opened at $16.51 on ...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q2 2023 Earnings Call Transcript August 8, 2023
Operator: Welcome to Acorda Therapeutics Second Quarter 2023 Financial and Business Update. At this time, all...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q2 2023 Earnings Call Transcript

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2023. INBRIJAs growth in the first half of 2023 improved significantly versus the first half of 2022, including a 42% increase in new prescription...

Acorda Therapeutics Reports Second Quarter 2023 Financial Results

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign. The campaign, For the Fighters, is based on direct feedback from people with Parkinsons (PwPs). It honors the fighting spirit of the Parkinsons...

Acorda Therapeutics Announces Launch of New INBRIJA Campaign: For The Fighters

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its second quarter 2023 update and financial results on Tuesday, August 8 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link...

Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023

Acorda Therapeutics, Inc. (NASDAQ:ACOR  Get Free Report) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 23,800 shares, an increase of 25.3% from the June 15th total of 19,000 shares. Approximately 2.0% of the company&#...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Short Interest Update

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine), and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa, and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in New York, NY.

Watchers	7,725
52-Wk Low	$5.22
52-Wk High	$24.80

Market Cap	$19.39M
Volume (M)	2,015.00
52-Wk High	$24.80
52-Wk Low	$5.22

ACOR Acorda Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals